financetom
Business
financetom
/
Business
/
Exact Sciences to Present New Data at Oncology Annual Meeting Confirming Prognostic Value of Breast Cancer Test
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Exact Sciences to Present New Data at Oncology Annual Meeting Confirming Prognostic Value of Breast Cancer Test
May 24, 2024 5:53 AM

08:31 AM EDT, 05/24/2024 (MT Newswires) -- Exact Sciences ( EXAS ) said Friday it will present 10 abstracts showing its screening and diagnostic portfolio, including new data confirming the predictive and prognostic value of the Oncotype DX Breast Recurrence Score test.

The company said that based on new data from two studies assessing Recurrence Score results, the test predicted breast cancer survival across various racial and ethnic groups.

The 10 abstracts will be presented at the American Society of Clinical Oncology Annual Meeting, May 31 to June 4, in Chicago, the company said.

Shares of Exact Sciences ( EXAS ) were down 6.6% in recent Friday premarket activity.

Price: 50.50, Change: -3.58, Percent Change: -6.62

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved